|
1
|
Merlo DF, Bruzzone M, Bruzzi P, Garrone E,
Puntoni R, Maiorana L and Ceppi M: Mortality among workers exposed
to asbestos at the shipyard of Genoa, Italy: A 55 years follow-up.
Environ Health. 17:942018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferrante D, Chellini E, Merler E, Pavone
V, Silvestri S, Miligi L, Gorini G, Bressan V, Girardi P, Ancona L,
et al: Italian pool of asbestos workers cohorts: Mortality trends
of asbestos-related neoplasms after long time since first exposure.
Occup Environ Med. 74:887–898. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Alley EW, Lopez J, Santoro A, Morosky A,
Saraf S, Piperdi B and van Brummelen E: Clinical safety and
activity of pembrolizumab in patients with malignant pleural meso
thelioma (KEYNOTE-028): Preliminary results from a non-randomised,
open-label, phase 1b trial. Lancet Oncol. 18:623–630. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Travis WD, Brambilla E, Burke AP, Marx A
and Nicholson AG: WHO classification of tumours of the Lung,
Pleura, Thymus and Heart. WHO Press WHO Classification of Tumors.
7. 4th edition. Lyon; France: 2015
|
|
5
|
Hegmans JP, Hemmes A, Hammad H, Boon L,
Hoogsteden HC and Lambrecht BN: Mesothelioma environment comprises
cyto kines and T-regulatory cells that suppress immune responses.
Eur Respir J. 27:1086–1095. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Anraku M, Cunningham KS, Yun Z, Tsao MS,
Zhang L, Keshavjee S, Johnston MR and de Perrot M: Impact of
tumor-infiltrating T cells on survival in patients with malignant
pleural mesothelioma. J Thorac Cardiovasc Surg. 135:823–829. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen DS and Mellman I: Oncology meets
immunology: The cancer-immunity cycle. Immunity. 39:1–10. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Freeman GJ, Long AJ, Iwai Y, Bourque K,
Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne
MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a
novel B7 family member leads to negative regu lation of lymphocyte
activation. J Exp Med. 192:1027–1034. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Keir ME, Francisco LM and Sharpe AH: PD-1
and its ligands in T-cell immunity. Curr Opin Immunol. 19:309–314.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Francisco LM, Salinas VH, Brown KE,
Vanguri VK, Freeman GJ, Kuchroo VK and Sharpe AH: PD-L1 regulates
the development, maintenance, and function of induced regulatory T
cells. J Exp Med. 206:3015–3029. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Teng F, Meng X, Kong L and Yu J: Progress
and challenges of predictive biomarkers of anti PD-1/PD-L1
immunotherapy: A systematic review. Cancer Lett. 414:166–173. 2018.
View Article : Google Scholar
|
|
12
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Files DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Marcq E, Pauwels P, Van Meerbeeck JP and
Smits EL: Targeting immune checkpoints: New opportunity for
mesothelioma treat ment? Cancer Treat Rev. 41:914–924. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hassan R, Thomas A, Patel MR, Nemunaitis
JJ, Bennouna J, Powderly JD, Taylor MH, Dowlati A, Chen F, Leach J,
et al: Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced
unresectable mesothelioma from the JAVELIN solid tumor phase Ib
trial: Safety, clinical activity, and PD-L1 expres sion. J Clin
Oncol. 34(15 Suppl): S8503. 2016. View Article : Google Scholar
|
|
15
|
Marcq E, Siozopoulou V, de Waele J, van
Audenaerde J, Zwaenepoel K, Santemans E, Heins N, Pauwels P, van
Meerbeeck JP and Smits EL: Prognostic and predic tive aspects of
the tumor immune microenvironment and immune checkpoints in
malignant pleural mesothelioma. Oncoimmunology. 6:e12612412016.
View Article : Google Scholar
|
|
16
|
Pasello G, Zago G, Lunardi F, Urso L, Kern
I, Vlacic G, Grosso F, Mencoboni M, Ceresoli GL, Schiavon M, et al:
Malignant pleural mesothelioma immune microenvironment and
checkpoint expres sion: Correlation with clinical-pathological
features and intratumor heterogeneity over time. Ann Oncol.
29:1258–1265. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Watanabe T, Okuda K, Murase T, Moriyama S,
Haneda H, Kawano O, Yokota K, Sakane T, Oda R, Inagaki H and
Nakanishi R: Four immunohistochemical assays to measure the PD-L1
expression in malignant pleural mesothelioma. Oncotarget.
9:20769–20780. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mansfield AS, Roden AC, Peikert T, Sheinin
YM, Harrington SM, Krco CJ, Dong H and Kwon EC: B7-H1 expression in
malignant pleural mesothelioma is associated with sarcomatoid
histology and poor prognosis. J Thorac Oncol. 9:1036–1040. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cedrés S, Ponce Aix S, Zugazagoitia J,
Sansano I, Enguita A, Navarro-Mendivii A, Martinez-Marti A,
Martinez P and Felip E: Analysis of expression of programmed cell
death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
PLoS One. 10:e01210712015. View Article : Google Scholar
|
|
20
|
Thapa B, Salcedo A, Lin X, Walkiewicz M,
Murone C, Ameratunga M, Asadi K, Deb S, Barnett SA, Knight S, et
al: The immune microenvironment, genome-wide copy number aberra
tions, and survival in mesothelioma. J Thorac Oncol. 12:850–859.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Combaz-Lair C, Galateau-Sallé F,
McLeer-Florin A, Le Stang N, David-Boudet L, Duruisseaux M,
Ferretti GR, Brambilla E, Lebecque S and Lantuejoul S: Immune
biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
Hum Pathol. 52:9–18. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Burtness B, Harrington KJ, Greil R,
Soulières D, Tahara M, De Castro G Jr, Psyrri A, Baste Rotllan N,
Neupane PC, Bratland A, et al: KEYNOTE-048: Phase 3 study of
first-line pembrolizumab (P) for recurrent/metastatic head and neck
squamous cell carcinoma (R/M HNSCC). In: Presented at ESMO
Congress; Munich. 2018
|
|
23
|
Minnema-Luiting J, Vroman H, Aerts J and
Cornelissen R: Heterogeneity in immune cell content in malignant
pleural mesothelioma. Int J Mol Sci. 19:–pii: E1041. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Baretti M and Le DT: DNA mismatch repair
in cancer. Pharmacol Ther. 189:45–62. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dudley JC, Lin MT, Le DT and Eshleman JR:
Microsatellite instability as a biomarker for PD-1 blockade. Clin
Cancer Res. 22:813–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cohen R, Pellat A, Boussion H, Svrcek M,
Lopez-Trabada D, Troudilloud I, Afchain P and André T:
Immunotherapy and metastatic colorectal cancers with microsatellite
instability or mismatch repair deficiency. Bull Cancer.
106:137–142. 2019. View Article : Google Scholar
|
|
27
|
Le DT, Durham JN, Smith KN, Wang H,
Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et
al: Mismatch repair deficiency predicts response of solid tumors to
PD-1 blockade. Science. 357:409–413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chalmers ZR, Connelly CF, Fabrizio D, Gay
L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J,
et al: Analysis of 100,000 human cancer genomes reveals the
landscape of tumor mutational burden. Genome Med. 9:342017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ponti G, Losi L, Martorana D, Priola M,
Boni E, Pollio A, Neri TM and Seidenari S: Clinicopathological and
biomolecular findings in Italian patients with multiple cutaneous
neurofibromas. Hered Cancer Clin Pract. 9:62011. View Article : Google Scholar
|
|
30
|
Neuman T, London M, Kania-Almog J, Litvin
A, Zohar Y, Fridel L, Sandbank J, Barshak I and Vainer GW: A
harmonization study for the use of 22C3 PD-L1 immunohistochemical
staining on ventana's platform. J Thorac Oncol. 11:1863–1868. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE 010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar
|
|
32
|
Rusch VW, Chansky K, Nowak AK, Rice D,
Kindler H, Gill RR and Travis WD: Malignant pleural mesothelioma.
Amin B: AJCC Cancer staging Manual. 8th edition. Switzerland:
Springer; pp. 457–468. 2017, View Article : Google Scholar
|
|
33
|
Taube JM: Unleashing the immune system:
PD-1 and PD-Ls in the pre-treatment tumor microenvironment and
correlation with response to PD-1/PD-L1 blockade. Oncoimmunology.
3:e9634132014. View Article : Google Scholar
|
|
34
|
Topalian SL, Sznol M, McDermott DF, Kluger
HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB,
Powderly JD, et al: Survival, durable tumor remission, and
long-term safety in patients with advanced melanoma receiving
nivolumab. J Clin Oncol. 32:1020–1030. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwai C, Gubens M, Horn L,
et al: Pembrolizumab for the treatment of non-small-cell lung
cancer. N Engl J Med. 372:2018–2028. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Valmary Degano S, Colpart P, Villeneuve L,
Monnien F, M'Hamndi L, Lang Averous G, Capovilla M, Bibeau F,
Laverriere MH, Verriele-Beurrier V, et al: Immunohistochemical
evaluation of two antibodies against PD-L1 and prognostic
significance of PD-L1 expression in epithelioid peritoneal malig
nant mesothelioma: A RENAPE study. Eur J Surg Oncol. 43:1915–1923.
2017. View Article : Google Scholar
|
|
39
|
Hamid O and Carvajal RD: Anti-programmed
death-1 and anti-programmed death-ligand 1 antibodies in cancer
therapy. Expert Opin Biol Ther. 13:847–861. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mittal D, Gubin MM, Schreiber RD and Smyth
MJ: New insights into cancer immunoediting and its three component
phases-elimination, equilibrium and escape. Curr Opin Immunol.
27:16–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Al-Shibli KI, Donnem T, Al-Saad S, Persson
M, Bremnes RM and Busund LT: Prognostic effect of epithelial and
stromal lymphocyte infiltration in non small cell lung cancer. Clin
Cancer Res. 14:5220–5227. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Galon J, Costes A, Sanchez-Cabo F,
Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M,
Berger A, Wind P, et al: Type, density, and location of immune
cells within human colorectal tumors predict clinical outcome.
Science. 313:1960–1964. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mahmoud SM, Paish EC, Powe DG, Macmillan
RD, Grainge MJ, Lee AH, Ellis IO and Green AR: Tumor-infiltrating
CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin
Oncol. 29:1949–1955. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yamada N, Oizumi S, Kikuchi E, Shinagawa
N, Konishi-Sakakibara J, Ishimine A, Aoe K, Gemba K, Kishimoto T,
Torigoe T and Nishimura M: CD8+ tumor-infiltrating lymphocytes
predict favorable prognosis in malignant pleural mesothelioma after
resection. Cancer Immunol Immunother. 59:1543–1549. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Burt BM, Rodig SJ, Tilleman TR, Elbardissi
AW, Bueno R and Sugarbaker DJ: Circulating and tumor-infiltrating
myeloid cells predict survival in human pleural mesothelioma.
Cancer. 117:5234–5244. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Arulananda S, Thapa B, Walkiewicz M,
Zapparoli GV, Williams DS, Dobrovic A and John T: Mismatch repair
protein defects and microsatellite instability in malignant pleural
meso thelioma. J Thorac Oncol. 13:1588–1594. 2018. View Article : Google Scholar : PubMed/NCBI
|
